Amitriptyline for Bladder Pain: 4 Trial Checks

The American Urological Association’s¹ 2022 guideline lists amitriptyline as an oral option for interstitial cystitis/bladder pain syndrome, with Grade B evidence. It calls for shared decisions about risks, benefits and alternatives, plus periodic reassessment. An option in a guideline still needs a discussion of the trial result and the person’s tolerance.¹

Who entered?

The trial randomized 271 treatment-naive adults with bladder pain and frequency; 83% were women, median age 38. Both groups received education, diet/fluid advice and bladder training.²

A bladder-pain diagnosis needs assessment rather than a prescription based on symptoms alone. The AUA recommends history, examination and laboratory checks to exclude other causes, including infection, and assessing incomplete emptying.¹ Our bladder-pain overview covers that diagnostic conversation.

What improved?

At 12 weeks, 74/135 taking amitriptyline versus 61/136 taking placebo reported moderate/marked overall improvement: 55% versus 45%, P=.12; difference 10 percentage points, 95% CI −2 to 22.²

Missing responses counted as failures: 24 versus 17. This was not evidence of equal effects.²

For a follow-up visit, separate pain during bladder filling, urgency, daytime trips and disrupted sleep. Write down the activities each symptom interrupts, alongside the treatment dates. Ask which of those problems the prescription is intended to change and what improvement would justify continuing it.

Why question the dose subgroup?

Researchers escalated 10–75 mg according to tolerance during six weeks. Among those maintaining at least 50 mg (or equivalent placebo) at 12 weeks, 48/62 versus 52/98 responded. This nonrandomized comparison selects dose tolerators; it does not prove higher-dose efficacy.²

Do not increase a prescription to copy the subgroup. Bring the dose you actually take, missed doses and symptoms that made a dose difficult to tolerate. Ask the prescriber how those observations affect the next decision.

Adverse events affected 119/135 versus 98/136. NIDDK funded the trial; authors disclosed Pfizer/Allergan relationships.²

What would change the prescription?

US labeling indicates amitriptyline for depression; bladder-pain prescribing is off-label. The label warns about urinary retention, glaucoma and cardiac problems. Older adults are particularly vulnerable to anticholinergic effects, including constipation, confusion and sedation, and falls.³

Review all medicines and supplements with the prescriber or pharmacist. Do not combine amitriptyline with an MAO inhibitor. Other antidepressants, tramadol and St John’s wort can increase serotonin-syndrome risk. Seek urgent help for fever with agitation and muscle stiffness. Ask about alcohol and driving because alertness can be impaired.³

The boxed warning concerns increased suicidal thinking/behavior in younger patients; people of all ages need monitoring for new mood or behavior changes. Call the prescriber immediately about these changes or suicidal thoughts. Discuss pregnancy or breastfeeding. Do not stop abruptly without speaking to the prescriber.³

The AUA says ineffective treatment should be stopped after reassessment, with alternatives considered.¹ Agree on a review date and a stopping or tapering plan before leaving the appointment. A specific question is: “My pain still interrupts the afternoon, and the morning drowsiness makes work difficult. Here are the dates and doses. What should change?”

Laugh, Sneeze, Jump discusses pain, difficult emptying and painful sex in “When Squeezing Is the Wrong Move.” It explains why those symptoms belong in an assessment for a floor that struggles to relax. Bring its symptom record to a clinician to discuss pain and emptying alongside the medicine review.